Approval · Notice of Compliance 25191 · 2021
SALOFALK SUPPOSITORIES: Notice of Compliance 25191
Issued February 11, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25191
- Date
- February 11, 2021
- Company
- Aptalis Pharma Canada UlcMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To update the product monograph (pm) with new safety information and to update the format of the pm to the 2016 format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SALOFALK SUPPOSITORIES | Not yet assigned | — |
Medicinal ingredients
- MESALAZINE 1,000 MG per SUP
- MESALAZINE 500 MG per SUP